story of the week
Efficacy of Biosimilar HD201 vs Referent Trastuzumab in ERBB2+ Breast Cancer Treated in the Neoadjuvant Setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial
JAMA Oncol 2022 Mar 03;[EPub Ahead of Print], X Pivot, MA Georgievich, V Shamrai, G Dzagnidze, H Fen, V Kaewkangsadan, F Petrelli, C Villanueva, LO Nikolaevich, J Hii, J Kim, S Pradhan, L Jaison, P Feyaerts, L Kaufman, MP Derde, GMC Bonamy, F Deforce, DG CoxFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.